$0 CO-PAY with the IMFINZI Patient Savings Program*

The IMFINZI Patient Savings Program is available to assist eligible, commercially insured patients with out-of-pocket costs for IMFINZI. There are no income requirements to participate.

Eligible patients with commercial insurance:

  • Can pay as little as $0 per infusion for IMFINZI
  • Can receive up to $100 per infusion of IMFINZI to help cover the cost of administration†

For more information, please visit azpatientsupport.com

*To be eligible, patients must be a resident of the United States or Puerto Rico and have commercial health insurance that covers medication costs for IMFINZI, but not the full cost to the patient. Patients are ineligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA or TRICARE, or where prohibited by law. Additional restrictions may apply. The IMFINZI Patient Savings Program covers the cost of IMFINZI and up to $100 administration cost per infusion, per drug, and does not cover costs for office visits, or any other associated costs. Offer is invalid for claims and transactions more than 365 days from the date of service. Individual costs and benefit design may vary by plan. Costs to patients may vary by plan. Please consult with individual plan for specific information.

†Patients who are residents of Massachusetts and Rhode Island are not eligible for infusion administration assistance. Patients are responsible for any cost associated with the infusion above the $100 per infusion assistance provided by the program.

Access 360 logo

Helping you access the care you need

If your doctor has prescribed IMFINZI, you may have questions.

The Access 360 program can help. We can answer questions about:

  • Insurance coverage
  • Out-of-pocket costs
  • Patient assistance programs

To learn more about the Access 360 program, please call 1-844-ASK-A360 (1-844-275-2360)

Monday-Friday, 8 AM-6 PM ET or visit www.MyAccess360.com

Explore Access 360financial-arrow
Access 360 logo

Looking for more IMFINZI resources?

Download tools for
your IMFINZI journey

financial-arrow

Important Safety Information

What is the most important information I should know about IMFINZI® (durvalumab)?

IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

What is IMFINZI?

IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used in combination with chemotherapy that contains platinum prior to surgery and alone after surgery when your NSCLC is able to be removed by surgery, and your tumor does not have an abnormal “EGFR” or “ALK” gene.

It is not known if IMFINZI is safe and effective in children.

IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called NSCLC.

  • IMFINZI may be used alone when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
  • IMFINZI may be used in combination with chemotherapy that contains platinum prior to surgery and alone after surgery when your NSCLC is able to be removed by surgery, and your tumor does not have an abnormal “EGFR” or “ALK” gene.

It is not known if IMFINZI is safe and effective in children.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

isi-icon-lung

Lung problems: cough, shortness of breath, and chest pain

isi-icon-intestine

Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; and severe stomach-area (abdomen) pain or tenderness

isi-icon-liver

Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), and bleeding or bruising more easily than normal

isi-icon-hormone-gland

Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; and changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

isi-icon-kidney

Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, and loss of appetite

isi-icon-skin

Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in mouth or nose, throat, or genital area; fever or flu-like symptoms; and swollen lymph nodes

isi-icon-pancreas

Pancreas problems: pain in your upper stomach area (abdomen), severe nausea or vomiting, and loss of appetite

isi-icon-head

Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with IMFINZI. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: Chest pain, irregular heartbeats, shortness of breath or swelling of ankles; confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems; tingling, numbness or weakness of the arms or legs; double vision, blurry vision, sensitivity to light, eye pain, changes in eye sight; persistent or severe muscle pain or weakness, muscle cramps, joint pain, joint stiffness or swelling; and low red blood cells and bruising

isi-icon-ivbag

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, and back or neck pain

isi-icon-ivbag

Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had

isi-icon-complications

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with IMFINZI. Your healthcare provider will monitor you for these complications

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with IMFINZI if you have severe side effects

Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you:

  • have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
  • have received an organ or tissue transplant, including corneal transplant
  • have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
  • have received radiation treatment to your chest area
  • have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
  • are pregnant or plan to become pregnant. IMFINZI can harm your unborn baby

    Females who are able to become pregnant:

    • Your healthcare provider will give you a pregnancy test before you start treatment with IMFINZI.
    • You should use an effective method of birth control during your treatment and for 3 months after the last dose of IMFINZI. Talk to your healthcare provider about birth control methods that you can use during this time.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with IMFINZI.
  • are breastfeeding or plan to breastfeed. It is not known if IMFINZI passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of IMFINZI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMFINZI?

IMFINZI can cause serious side effects (see above).

The most common side effects of IMFINZI when used alone in adults with non-small cell lung cancer (NSCLC) that cannot be removed by surgery include cough, feeling tired, inflammation in the lungs, upper respiratory tract infections, shortness of breath, and rash.

The most common side effects of IMFINZI when used with platinum-containing chemotherapy in adults with NSCLC that can be removed by surgery include low red blood cells (anemia), nausea, constipation, feeling tired, muscle or bone pain, and rash.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.

Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information including Medication Guide for IMFINZI.

What is IMFINZI?

IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called NSCLC.

  • IMFINZI may be used alone when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
  • IMFINZI may be used in combination with chemotherapy that contains platinum prior to surgery and alone after surgery when your NSCLC is able to be removed by surgery, and your tumor does not have an abnormal “EGFR” or “ALK” gene.

It is not known if IMFINZI is safe and effective in children.

IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used in combination with chemotherapy that contains platinum prior to surgery and alone after surgery when your NSCLC is able to be removed by surgery, and your tumor does not have an abnormal “EGFR” or “ALK” gene.

It is not known if IMFINZI is safe and effective in children.

Please see Full Prescribing Information including Medication Guide for IMFINZI.

US-Flag

This product information is intended for US consumers only.

IMFINZI is a registered trademark and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies.

©2025 AstraZeneca. All rights reserved. US-82703; US-106879 Last Updated 12/25

Read full Important Safety Information

What is IMFINZI?

Expand

Important Safety Information

What is the most important information I should know about IMFINZI® (durvalumab)?

IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect...

IMFINZI is a medicine that may treat certain cancers by working with your immune system....

Read full Important Safety Information

What is IMFINZI?

IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called NSCLC.

  • IMFINZI may be used alone when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time

Minimize